Market Place
Sourcing Support
Innovent`s IBI310 Plus Sintilimab Neoadjuvant Data For Colon Cancer At ASCO
02 Jun 2024 //
PR NEWSWIRE
HUTCHMED & Innovent NDA Acceptance in China for Fruquintinib with Sintilimab
01 Apr 2024 //
GLOBENEWSWIRE
Innovent First Dosed in Ph 3 (Neoshot) with Sintilimab for Colon Cancer
26 Mar 2024 //
PR NEWSWIRE
Innovent and Xuanzhu Enter into Clinical Trial Collaboration
27 Dec 2023 //
PR NEWSWIRE
HUTCHMED has Completed Enrollment of Ph II/III of Fruquintinib with Sintilimab
12 Dec 2023 //
GLOBENEWSWIRE
Innovent Announces the Phase 3 Results Published in JAMA Evaluating Sintilimab
05 Dec 2023 //
PR NEWSWIRE
Hutchmed Receives BTD for Fruquintinib Combination with Sintilimab
19 Jul 2023 //
GLOBENEWSWIRE
Innovent & RemeGen Enter into Trial Collab Invesg Combination Therapy of TYVYT
25 Jun 2023 //
PR NEWSWIRE
Synlogic’s SYNB1934 receives orphan drug status from US FDA
10 May 2023 //
PHARMACEUTICAL TECHNOLOGY
The China NMPA Approves TYVYT® in Combination with Bevacizumab
09 May 2023 //
PR NEWSWIRE
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus
07 May 2023 //
PR NEWSWIRE
Innovent Releases Final Analysis Results of ORIENT-16 Ph3 Study of Sintilimab
17 Apr 2023 //
PR NEWSWIRE
Innovent Presents Phase Ib Clinical Data Update of IBI110m at European Society
08 Dec 2022 //
PRNEWSWIRE
Innovent Announced Data of Multiple Trials Will be Presented at ESMO-IO and ASH
27 Nov 2022 //
PRNEWSWIRE
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib with Sintilimab
27 Oct 2022 //
GLOBENEWSWIRE
Innovent`s Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients
07 Sep 2022 //
PRNEWSWIRE
Sanofi and Innovent Biologics to collaborate on oncology medicines
05 Aug 2022 //
LABIOTECH
Innovent and Laekna begin Dosing with Three-drug Combination in PI/II Study
31 Jul 2022 //
PRNEWSWIRE
Innovent and Lilly Jointly Announce the Approval of TYVYT by China NMPA
20 Jun 2022 //
PRNEWSWIRE
U.S. FDA declines to approve Lilly/Innovent lung cancer drug
25 Mar 2022 //
REUTERS
Coherus and Junshi uncork win for PD-1 drug in esophageal cancer
05 Mar 2022 //
ENDPTS
After Lilly`s sintilimab loses, China-only oncology trials face reality at FDA
11 Feb 2022 //
ENDPTS
FDA recommends against Eli Lilly’s PD-1, doubting China-made cancer drugs
11 Feb 2022 //
ENDPTS
Innovent, Eli Lilly Show Final Results of Phase Ib Study of TYVYT
21 Jan 2022 //
BIOSPACE
Innovent Announces NMPA of China Acceptance of sNDA for TYVYT
23 Dec 2021 //
PRNEWSWIRE
Innovent Announces NMPA of China Acceptance of sNDA for TYVYT
23 Dec 2021 //
PRNEWSWIRE
Innovent Releases ORIENT-31 Phase 3 Study Results in EGFR-mutated NSCLC
20 Nov 2021 //
PRNEWSWIRE
Innovent Announces NMPA Acceptance of a sNDA for Sintilimab
03 Nov 2021 //
PRNEWSWIRE
Good news for Lilly as sintilimab hits the spot in lung cancer again
19 Oct 2021 //
PHARMAPHORUM
Langer, Ciechanover godfather the latest AI upstart; & more
18 Oct 2021 //
ENDPTS
Innovent Announces Sintilimab Met Primary Endpoint atAnalysis of ORIENT31 Trial
18 Oct 2021 //
TRIALSITES
Innovent Announces Phase 3 Study of Sintilimab, Has Met Primary Endpoint
17 Oct 2021 //
PRNEWSWIRE
Innovent Announces NMPA Acceptance of Suppl. NDA for Sintilimab & Chemotherapy
22 Sep 2021 //
PRNEWSWIRE
Eli Lilly out to crash sintilimab with `disruptive` pricing; Innovent
20 Sep 2021 //
ENDPTS
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy
17 Sep 2021 //
PRNEWSWIRE
Innovent to Present Data on Sintilimab and Other Molecules at the ESMO Congress
29 Aug 2021 //
PRNEWSWIRE
Innovent’s sintilimab meets primary goal in Phase III gastric cancer trial
16 Aug 2021 //
CLINICALTRIALSARENA
InxMed`s IN10018 Receives U.S. FDA Fast Track Designation for Ovarian Cancer
15 Aug 2021 //
PR NEWSWIRE
Innovent phase 3 ORIENT-15 study meets endpoints
23 Jun 2021 //
PHARMABIZ
Sintilimab Chemotherapy Cobo Meets Overall Survival Primary Endpoint
22 Jun 2021 //
PRNEWSWIRE
Innovent Announces NMPA Acceptance of a Supplemental NDA for TYVYT®
12 Jan 2021 //
PRNEWSWIRE
Innovent Releases Ph3 Results of TYVYT® (Sintilimab Injection) in Comb BYVASDA®
23 Nov 2020 //
PRNEWSWIRE
Innovent Announces Positive Results with Lilly on TYVYT®
06 Oct 2020 //
PRNEWSWIRE
Innovent Bio`s expanded collaboration with Lilly for Tyvyt now effective
06 Oct 2020 //
SEEKING ALPHA
Innovent Biologics Announces Study Data of TYVYT®In Combination with BYVASDA®
28 Sep 2020 //
ASIAONE
Innovent & Lilly At ESMO Presents Ph Iii Results Of Tyvyt® + Alimta®
20 Sep 2020 //
PRNEWSWIRE
Innovent Announces NMPA Marketing Approval for SULINNO (Adalimumab Injection)
03 Sep 2020 //
PRNEWSWIRE
China NMPA accepts Innovent & Eli Lilly’s sNDA for Tyvyt in combo gemcitabine
12 Aug 2020 //
PHARMABIZ
Innovent & Eli Lilly Announce Acceptance of a sNDA of TYVYT®
12 Aug 2020 //
BIOSPACE
Innovent Announces First Patient Dosed in a Ph 1b Clinical Trial of Sintilimab
08 Jul 2020 //
PRNEWSWIRE
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Antibody IBI310
02 Jun 2020 //
PRNEWSWIRE
Innovent Biologics and MD Anderson Announce a Strategic CollaborationTYVYT®
18 May 2020 //
PRNEWSWIRE
TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary of Overall Survival
13 May 2020 //
PRNEWSWIRE
Tyvyt® Combined with Gemzar® and Platinum Chemotherapy Met Predefined Endpoint
06 May 2020 //
PRNEWSWIRE
Innovent & Eli Lilly Announce NMPA Acceptance of a snda for Sintilimab
23 Apr 2020 //
PR NEWSWIR
Innovent Announces 1st Patient Dosed in Ph I Trial of Anti-LAG-3 Antibody
05 Dec 2019 //
PR NEWSWIRE
Innovent Presents Co-developed Cancer-Fighting Tyvyt at CIIE 2019 with Eli Lilly
01 Dec 2019 //
PR NEWSWIRE
Tyvyt is Included in National Reimbursement Drug List
28 Nov 2019 //
PR NEWSWIRE
Innovent and Chi-Med expand global collaboration for solid tumor treatment
10 Oct 2019 //
BIOSPECTRUM ASIA
Innovent Update on Results of IBI305 on Non-squamous Cell Lung Cancer
19 Sep 2019 //
BIOSPACE
